SAN DIEGO and DEERFIELD, Ill., Nov. 11, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) and Takeda Pharmaceuticals U.S.A., Inc. (Takeda), today announced multiple Contrave® (naltrexone sustained release (SR)/bupropion SR) abstracts accepted for poster presentations and an oral presentation at the upcoming ObesityWeek meeting. This meeting will be held November 11-16, 2013 in Atlanta at the Georgia World Congress Center.
Details on the presentation times are as follows:
Oral Presentation: Thursday, November 14, 2013 - Abstract T-36-OR, Presentation time 3:00-4:30 EST, Georgia World Congress Center
Presenter: Kevin D. Hall, Ph.D.; National Institutes of Health, NIDDK, Bethesda, MD, USA.
Title: Dynamical Systems Modeling of Caloric Intake and Body Composition with Combination Naltrexone/Bupropion Therapy
Poster Presentation: Friday, November 15, 2013 - Abstract T-740-P, Presentation time 12:00-1:30PM EST, Georgia World Congress Center, Exhibit Hall A
Presenter: Raymond A Plodkowski, MD; Scripps Clinic, La Jolla, CA, USA.
Title: Early achievement of significant weight loss with naltrexone/bupropion is associated with additional weight loss at one year – an integrated analysis of four Phase 3 trials
Poster Presentation: Friday, November 15, 2013 - Abstract T-741-P, Presentation time 12:00-1:30PM EST, Georgia World Congress Center, Exhibit Hall A
SOURCE Orexigen Therapeutics, Inc.; Takeda Pharmaceuticals, U.S.A., Inc.
Copyright©2012 PR Newswire.
All rights reserved
Related medicine technology :
1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
10. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
11. Orexigen Therapeutics to Present at Upcoming Investor Conferences